244 related articles for article (PubMed ID: 26927249)
1. Low-dose add-back therapy during postoperative GnRH agonist treatment.
Tsai HW; Wang PH; Huang BS; Twu NF; Yen MS; Chen YJ
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis.
Kim NY; Ryoo U; Lee DY; Kim MJ; Yoon BK; Choi D
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):85-9. PubMed ID: 20832162
[TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
5. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
6. Steroidal 'add-back' therapy in patients treated with GnRH agonists.
Freundl G; Gödtke K; Gnoth C; Godehardt E; Kienle E
Gynecol Obstet Invest; 1998; 45 Suppl 1():22-30; discussion 35. PubMed ID: 9628521
[TBL] [Abstract][Full Text] [Related]
7. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
[TBL] [Abstract][Full Text] [Related]
9. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
[TBL] [Abstract][Full Text] [Related]
10. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
Mettler L
Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
[TBL] [Abstract][Full Text] [Related]
11. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
12. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
13. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain.
Hurst BS; Gardner SC; Tucker KE; Awoniyi CA; Schlaff WD
JSLS; 2000; 4(2):97-101. PubMed ID: 10917114
[TBL] [Abstract][Full Text] [Related]
14. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
Divasta AD; Laufer MR; Gordon CM
J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
[TBL] [Abstract][Full Text] [Related]
15. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
Surrey ES
Fertil Steril; 1999 Mar; 71(3):420-4. PubMed ID: 10065775
[TBL] [Abstract][Full Text] [Related]
16. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
17. Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis.
Lee DY; Park HG; Yoon BK; Choi D
Obstet Gynecol Sci; 2016 Jan; 59(1):32-8. PubMed ID: 26866033
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
19. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
